Hobert succeeds Kerpelman as head of Kodak’s Health Group
Kodak’s Health Group has a new head. On Feb.16, the company appointed Kevin J. Hobert president of the group and senior vice president of Eastman Kodak. He will report to Antonio M. Perez, Kodak’s president and COO.
Kodak's Health Group has a new head. On Feb.16, the company appointed Kevin J. Hobert president of the group and senior vice president of Eastman Kodak. He will report to Antonio M. Perez, Kodak's president and COO.
Hobert replaces Daniel Kerpelman, who is leaving the company to become CEO
of SGS Group, a publicly traded European firm. Kerpelman will assume his new duties April 11. SGS Group, founded in 1878, runs about 1000 offices and laboratories around the world specializing in inspection, verification, testing, and certification. Services are provided to a number of industries, including diagnostics.
Hobert previously served as general manager of Kodak's Digital Capture Systems and vice president of its Health Group. Under Hobert, Kodak's computed radiography business has attained the number two position worldwide, according to the company. Hobert also recently ushered Kodak's mammography CAD system through the FDA approval process.
Hobert joined Kodak in 2002 from GE Medical Systems, after 11 years in medical imaging. He was responsible for leading GEMS' global businesses addressing digital, analog and mobile radiography and multipurpose fluoroscopy. Hobert holds a bachelor of science in physics from the University of Wisconsin.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
